Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non Operating Income (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Non Operating Income readings, the most recent being -$661000.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 178.97% to -$661000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $302000.0, a 92.22% decrease, with the full-year FY2025 number at $1.8 million, down 53.88% from a year prior.
  • Non Operating Income hit -$661000.0 in Q4 2025 for Enanta Pharmaceuticals, down from -$282000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.9 million in Q2 2023 to a low of -$661000.0 in Q4 2025.
  • Median Non Operating Income over the past 5 years was $667500.0 (2024), compared with a mean of $709550.0.
  • Biggest five-year swings in Non Operating Income: skyrocketed 620.39% in 2023 and later tumbled 178.97% in 2025.
  • Enanta Pharmaceuticals' Non Operating Income stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then dropped by 13.7% to $857000.0 in 2023, then dropped by 2.33% to $837000.0 in 2024, then tumbled by 178.97% to -$661000.0 in 2025.
  • The last three reported values for Non Operating Income were -$661000.0 (Q4 2025), -$282000.0 (Q3 2025), and $667000.0 (Q2 2025) per Business Quant data.